Trigeminal neuralgia surgical options

Trigeminal neuralgia is a clinical syndrome of recurrent unilateral paroxysms lasting fractions of a second to about 2 minutes, severe, electric-shock-like and confined to trigeminal divisions, often triggered by light touch, chewing, talking, brushing teeth or cold air. Classical TN has neurovascular compression with morphological nerve change; idiopathic TN has no identified cause; secondary TN results from multiple sclerosis, tumour or another lesion. Painful trigeminal neuropathy and persistent idiopathic facial pain are different syndromes and respond differently to destructive procedures.

Diagnosis precedes procedure selection. Examine facial sensation in each division, corneal reflexes, muscles of mastication and other cranial nerves, and obtain dental assessment where indicated. MRI with high-resolution trigeminal sequences and vascular imaging excludes tumour, demyelination and other structural causes and assesses neurovascular contact. Because contact is common in asymptomatic people, imaging cannot replace the clinical phenotype; compression with displacement or atrophy is more relevant to MVD planning.

Carbamazepine and oxcarbazepine are first-line long-term medicines under EAN guidance. They require interaction, blood-count, liver and sodium safety appropriate to the agent and person. Surgery should be offered when medicine no longer controls pain sufficiently or adverse effects are unacceptable. Shared decision-making should occur before repeated crises, taking account of frailty, anticoagulation, anaesthetic risk, multiple sclerosis, sensory findings and the person’s priorities about durability versus invasiveness and numbness.

Microvascular decompression uses a posterior-fossa craniotomy to separate an offending vessel from the trigeminal root. It is non-ablative and recommended as first-line surgery in classical TN. It generally provides the most durable pain freedom, especially with clear neurovascular compression, but carries risks of CSF leak, infection, hearing loss, facial weakness or numbness, cerebellar/brainstem injury, stroke, anaesthesia and rarely death. A vascular contact without a matching phenotype does not justify surgery.

Percutaneous procedures access the trigeminal ganglion or root through the foramen ovale. Radiofrequency thermocoagulation can target divisions; balloon compression mechanically injures fibres; glycerol rhizolysis creates chemical injury. Pain relief is often immediate or rapid and the physiological burden is lower than open posterior-fossa surgery, making them useful for older or less fit patients and after recurrence. Trade-offs include expected facial numbness, dysaesthesia, masticatory weakness, corneal hypoesthesia—especially when V1 fibres are affected—anaesthesia dolorosa and recurrence. Repeat procedures accumulate sensory injury.

Stereotactic radiosurgery focuses radiation at the trigeminal root without an incision. It suits patients who prefer a non-invasive approach or are poor candidates for open surgery, but analgesia typically develops after a delay rather than immediately. Facial numbness, dysaesthesia, recurrence and radiation-related uncertainty must be discussed. It is therefore a poor sole response to a crisis in which the patient cannot drink today; acute medical rescue and hydration remain necessary.

No ablative technique is universally superior. EAN could not recommend one neuroablative procedure over another because comparative evidence is limited; the 2025 evidence review similarly grades much evidence very low. Secondary TN needs cause-specific care: multiple-sclerosis-related pain may have less predictable MVD benefit unless convincing neurovascular compression coexists, while tumour needs a tumour pathway. Recurrence after any procedure requires phenotype and imaging review rather than automatic repetition.